HNN3.0
Register
Register
Register

Project cooperationUpdated on 22 January 2026

Allogeneic Cell therapy of cancer an autoimmune diseases

Principal Investigator at IRCCS Azienda Ospedaliera Metropolitana, plesso Ospedale Policlinico San Martino

Genova, Italy

About

-Development and validation of off-the-shelf cell therapies

-Multi-omics data available for deep characterization and identification of target gene to implement safety and efficacy

-Standardization of manufacturing

-Pre-clinical and clinical grade manufacturing

-In vitro and in vivo models

-expertise in cancer vaccines and their combination with other therapies

-genomic profile of cancer stem cells and their susceptibility to cell therapy

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
  • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
  • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Similar opportunities

  • Project cooperation

    New in vitro assay methodologies

    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

    Hanne Haslene-Hox

    Seinor research scientist at SINTEF Industry

    Trondheim, Norway

  • Project cooperation

    Human-relevant bone marrow-on-chip and AI-guided NAMs to predict and prevent resistance to targeted therapies in hematologic malignancies

    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

    Vladan Čokić

    Head of Department of molecular oncology at Institute for Medical Research University of Belgrade

    Belgrade, Serbia

  • Project cooperation

    Seeking collaboration in ATMP and New Approach Methodologies

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

    Grzegorz Chodaczek

    Immunotherapy Group Leader at Łukasiewicz Research Network - PORT Polish Center for Technology Development

    Wrocław, Poland